A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors

Open to people ages 18 years and up

• Participants who are intolerant or resistant to standard treatment for selected solid tumors
• at least one measurable or non-measurable lesion, not previously irradiated, as defined by RECIST 1.1
• ECOG Performance Status 0 or 1, 2 with approval
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function
• Resolved acute effects of any prior therapy

• Known active uncontrolled or symptomatic CNS metastases
• Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies or investigational drug(s) taken on another study) prior to study entry
• Active or history of autoimmune disease requiring >10mg/day prednisone or other concurrent immunosuppressive therapy
• Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as defined in protocol
• Retinal or other serious ophthalmic disorders as defined in protocol
• Clinically significant cardiac disease as defined in protocol
• Inability to consume or absorb study drug
• Known or suspected hypersensitivity to PF-07265807
• Prohibited concomitant medications as defined in protocol